Vir Biotechnology Inc (VIR) is a Healthcare · Biotechnology company listed on NASDAQ. Price $10.49 (-3.94%), Market cap $1.50B, 52-week low–high $4.28 ~ $11.09.
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amende
Financial statements, price targets, institutional (13F) holdings and related news for Vir Biotechnology Inc are updated in real time on BlackAll Trade.
Vir Biotechnology Inc trades at $10.49 (-3.94%). Real-time quotes and charts are available on BlackAll Trade.
Vir Biotechnology Inc has a market cap of about $1.50B.
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and international